teladoc glp-1 receptor agonist weight management diabetes treatments Health Partners with Eli Lilly to Offer Self-Pay Option for Oral GLP-1-Based Therapeutics in the

Our study revealed a novel role for GLP-1 and its derivatives in pain relief, suggesting exendin 2029 as a promising therapeutic candidate

BozzettoLAnnuzziGRagucciMDi DonatoODella PepaGDella CorteGet al

LIMITATIONS, REASONS FOR CAUTION Study limitations include the absence of data regarding medication compliance post prescription redemption, potential misclassification due to parallel importation, and the inability to control for unmeasured confounding factors

The honest answer: berberine may support metabolic markers and modestly improve some obesity indices, but it is not an Ozempic replacement

In this issue of Diabetologia , Maida et al

The promising obesity outcomes enabled by drugs such as Wegovy have prompted other drug manufacturers to pursue their own development efforts to help claim their share of this unprecedented market opportunity